NLRP3 and cardiovascular disorder: Furthermore, TMAO promotes the release of inflammatory factors by activating the NLRP3 inflammasome, thereby promoting vascular calcification, myocardial fibrosis, and vascular inflammation aggravating cardiovascular disease (Chen et al., 2017; Liu et al., 2019; Zhang et al., 2020).